• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients Clinical Sciences
Conclusions— Anticoagulant treatment with apixaban versus aspirin in low-risk patients, as identified using CHADS2 or CHA2DS2–VASc, is projected to increase life expectancy and provide clinical benefits that are cost effective.
Source: Stroke - September 28, 2015 Category: Neurology Authors: Lip, G. Y. H., Lanitis, T., Mardekian, J., Kongnakorn, T., Phatak, H., Dorian, P. Tags: Primary prevention, Cerebrovascular disease/stroke, Anticoagulants, Antiplatelets Clinical Sciences Source Type: research

0528 : Incidence and predictors of stroke among patients with chronic heart failure
Conclusion In our study, it seems that femal patients were at lower risk of stroke, in the other hand, prior history of myocardial fraction was predictor of stroke; however the severity of left ventricule systolic dysfunction did not influence the risk of embolic events. The author hereby declares no conflict of interest
Source: Archives of Cardiovascular Diseases Supplements - June 15, 2016 Category: Cardiology Source Type: research

Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation.
Conclusion: Variation in published AF stroke rates for patients not receiving anticoagulant therapy results in multifold variation in the net clinical benefit of anticoagulation. Guidelines should better reflect the uncertainty in current thresholds of stroke risk score for recommending anticoagulation. Primary Funding Source: None. PMID: 30264130 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - September 25, 2018 Category: Internal Medicine Authors: Shah SJ, Eckman MH, Aspberg S, Go AS, Singer DE Tags: Ann Intern Med Source Type: research

Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation: A Secondary Analysis of the AVERROES Study Brief Reports
Conclusions— Female patients with atrial fibrillation had higher ischemic stroke rates compared with male patients, but the relative effects of apixaban compared with aspirin on both ischemic stroke and bleeding were similar in men and women.
Source: Stroke - June 23, 2014 Category: Neurology Authors: Lip, G. Y. H., Eikelboom, J., Yusuf, S., Shestakovska, O., Hart, R. G., Connolly, S., on behalf of the AVERROES Investigators Tags: Other anticoagulants, Thrombosis risk factors Brief Reports Source Type: research

Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry
The objective of the present prospective study, using data from 2008, was to evaluate the prevalence of AA (atrial fibrillation/flutter) in patients with stroke and the impact of implementing AF guidelines. Methods: The prevalence of AA was studied in patients diagnosed with stroke from January 1 to December 31, 2008 in the population-based Stroke Registry of Brest, France (total population, 363,760 according to the 2008 census, with 295,553 aged 15 years or older). Guidelines implementation was assessed in terms of antithrombotic therapy (VKA, antiplatelet agent, none), and the CHADS2 (Congestive heart failure, Hypertens...
Source: BMC Geriatrics - June 11, 2015 Category: Geriatrics Authors: Virginie JannouSerge TimsitEmmanuel NowakFrançois RouhartPhilippe GoasFrançois-Mathias MerrienIrina Viakhireva-DovganyukAnne Tirel-BadetsArmelle Gentric Source Type: research

Prevalence, Mechanisms, and Management of Ischemic Stroke in Heart Failure Patients
Semin Neurol DOI: 10.1055/s-0041-1726329Heart failure (HF) and stroke, two of the major causes of death worldwide, are closely associated. Although atrial fibrillation (AF), which occurs in more than half of patients with HF, is a major risk factor for stroke, there is a great deal of evidence that HF itself increases the risk of stroke independent of AF. The main mechanism of stroke appears to be thromboembolism. However, previous studies have failed to demonstrate the benefit of warfarin in patients with HF without AF, as the benefit of stroke prevention was counteracted by the increased incidence of major bleeding. Rece...
Source: Seminars in Neurology - April 13, 2021 Category: Neurology Authors: Seol, Hyeyoung Kim, Jong S. Tags: Review Article Source Type: research

Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research

Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology
ConclusionsThe study reveals a high prevalence and diverse distribution of AF in patients with cardiomyopathies, inadequate anticoagulation regimen, and high risk of stroke/TIA in this population.
Source: ESC Heart Failure - September 16, 2020 Category: Cardiology Authors: Katarzyna Mizia ‐Stec, Alida L.P. Caforio, Philippe Charron, Juan R. Gimeno, Perry Elliott, Juan Pablo Kaski, Aldo P. Maggioni, Luigi Tavazzi, Angelos G. Rigopoulos, Cecile Laroche, Attila Frigy, Elisabetta Zachara, Maria Luisa Pena‐Pena, Tags: Original Research Article Source Type: research

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial
Background: Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may have a higher risk of thrombosis and/or bleeding than VKA-experienced patients.Methods and results: Using data from ARISTOTLE, we assessed baseline characteristics and the treatment effect of apixaban versus warfarin in the VKA-naive and VKA-experienced cohorts. We compared rates of study drug discontinuation and time-in-therapeutic range. Overall, 7,800 (43%) were VKA naive, and 10,401 were VKA experienced. At baseline, both groups were similar with respect to age and congestive heart failure, hypertension, age, diabetes, stroke sco...
Source: American Heart Journal - July 26, 2013 Category: Cardiology Authors: David A. Garcia, Lars Wallentin, Renato D. Lopes, Laine Thomas, John H. Alexander, Elaine M. Hylek, Jack Ansell, Michael Hanna, Fernando Lanas, Greg Flaker, Patrick Commerford, Denis Xavier, Dragos Vinereanu, Hongqiu Yang, Christopher B. Granger Tags: Electrophysiology Source Type: research

Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke
ConclusionsIn a large, real-world cardiac outpatient population of AF patients with a moderate to high risk of stroke, more than 1 in 3 were treated with aspirin alone without OAC. Specific patient characteristics predicted prescription of aspirin therapy over OAC.
Source: Journal of the American College of Cardiology - June 21, 2016 Category: Cardiology Source Type: research

Stroke prevention, 1-year clinical outcomes and healthcare resource utilization in patients with atrial fibrillation in France: Data from the GARFIELD-AF registry.
CONCLUSIONS: Patients enrolled in France had higher rates of mortality and stroke/systemic embolism than in GARFIELD-AF overall. Conversely, the risk of major bleeding was not higher. PMID: 29861295 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - May 31, 2018 Category: Cardiology Authors: Le Heuzey JY, Bassand JP, Berneau JB, Cozzolino P, D'Angiolella L, Doucet B, Mantovani LG, Martelet M, Mouallem J, Muller JJ, Pieper K, GARFIELD-AF Investigators Tags: Arch Cardiovasc Dis Source Type: research

Study On Drug Utilization And Assessment Of Stroke Risk Using Chads2 And Cha2ds2-Vasc Scoring In Elderly Patients With Non-Valvular Atrial Fibrillation
Stroke Risk Stratification in AF patients of can be done using CHADS2 (Congestive heart failure, Hypertension, Age ≥75, DM, prior Stroke/TIA [2 points] ); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection fraction ≤35%, Hypertension, Age ≥75 [2 points], DM, prior Stroke/TIA/thromboembolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets (Aspirin and Clopidogrel).
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: T. Raj, S. Bonthu, S.R. Mallayasamy Source Type: research

Stroke prevention in atrial fibrillation: evidence from real-life studies
Atrial fibrillation (AF) is an increasing public health issue, especially owing to an accompanying five-fold increased risk of stroke. Anticoagulants are the cornerstone of therapy for stroke prevention in AF. The clinical benefits of vitamin K antagonists (VKAs; namely warfarin) shown in randomized controlled trials (RCTs) have been challenged when used in clinical practice by issues including the need for international normalized ratio (INR) monitoring, food and drug interactions, low time in the therapeutic range in substantial numbers of patients, and serious bleeding events. Combined, these have led to both an under-i...
Source: European Journal of Heart Failure Supplements - July 10, 2015 Category: Cardiology Authors: Akao, M., Beyer-Westendorf, J., Goto, S., Peterson, E. Tags: Articles Source Type: research

Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation
Oral anticoagulation is the long-term standard of care for preventing stroke in patients with atrial fibrillation (AF). However, anticoagulation is associated with an increased risk of bleeding, such that its use should be based on the absolute risks of stroke and bleeding, and the relative benefit–risk profile of the individual patient. Non-vitamin K antagonist oral anticoagulants, including rivaroxaban, are alternatives to vitamin K antagonists such as warfarin in this setting, and are supported in treatment guidelines as the optimal choice for patients with AF at moderate to high risk of stroke. Rivaroxaban can be...
Source: European Journal of Heart Failure Supplements - April 20, 2016 Category: Cardiology Authors: Antoniou, S., Amara, W. Tags: Articles Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12